# A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses

> **NCT05741294** · PHASE4 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 334 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Tirbanibulin 2.5 mg ointment

## Key facts

- **NCT ID:** NCT05741294
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-20
- **Primary completion:** 2024-01-19
- **Final completion:** 2024-01-19
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05741294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05741294, "A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05741294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*